Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brendan M Weiss

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Kidney International|May 16, 2018
A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin depositsRamnika Gumber, Jordana B Cohen, Matthew B Palmer, et al.
Blood|May 26, 2016
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myelomaJakub Krejcik, Tineke Casneuf, Inger S Nijhof, et al.
Blood|June 23, 2017
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myelomaAjai Chari, Attaya Suvannasankha, Joseph W Fay, et al.
JACC. Cardiooncology|November 29, 2022
Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA TrialMonique C Minnema, Angela Dispenzieri, Giampaolo Merlini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple MyelomaTimothy A Brighton, Amit Khot, Simon J Harrison, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2015
Outpatient Autologous Stem Cell Transplantation for Patients With MyelomaThomas M Paul, Stephen V Liu, Elise A Chong, et al.
Blood|May 25, 2016
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myelomaSaad Z Usmani, Brendan M Weiss, Torben Plesner, et al.
The Lancet. Haematology|May 30, 2020
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trialsSaad Z Usmani, Hareth Nahi, Torben Plesner, et al.
The New England Journal of Medicine|September 10, 2015
Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaAlfred L Garfall, Marcela V Maus, Wei-Ting Hwang, et al.
Blood|April 4, 2020
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDAGiovanni Palladini, Efstathios Kastritis, Mathew S Maurer, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Kidney International|May 16, 2018
A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin depositsRamnika Gumber, Jordana B Cohen, Matthew B Palmer, et al.
Blood|May 26, 2016
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myelomaJakub Krejcik, Tineke Casneuf, Inger S Nijhof, et al.
Blood|June 23, 2017
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myelomaAjai Chari, Attaya Suvannasankha, Joseph W Fay, et al.
JACC. Cardiooncology|November 29, 2022
Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA TrialMonique C Minnema, Angela Dispenzieri, Giampaolo Merlini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple MyelomaTimothy A Brighton, Amit Khot, Simon J Harrison, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2015
Outpatient Autologous Stem Cell Transplantation for Patients With MyelomaThomas M Paul, Stephen V Liu, Elise A Chong, et al.
Blood|May 25, 2016
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myelomaSaad Z Usmani, Brendan M Weiss, Torben Plesner, et al.
The Lancet. Haematology|May 30, 2020
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trialsSaad Z Usmani, Hareth Nahi, Torben Plesner, et al.
The New England Journal of Medicine|September 10, 2015
Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaAlfred L Garfall, Marcela V Maus, Wei-Ting Hwang, et al.
Blood|April 4, 2020
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDAGiovanni Palladini, Efstathios Kastritis, Mathew S Maurer, et al.
Pageof 6